Switching to Genoya Plus Prezista Maintains Viral Suppression, Improves Renal Markers

March 15, 2017

Switching from a suppressive five-drug regimen to fixed-dose elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks. Kidney markers improved in people who changed to the two-pill combination.

The licensing of new antiretrovirals and new antiretroviral classes has improved chances of controlling HIV replication even in people with multidrug-resistant virus. But some salvage regimens include several individual agents, sometimes with dietary restrictions. Once-daily E/C/F/TAF (Genvoya) has been licensed in the United States and the European Union. The once-daily protease inhibitor darunavir (Prezista) can be boosted by ritonavir (Norvir) or cobicistat (Tybost). U.S. and Canadian researchers conducted this open-label randomized trial to test the efficacy and safety of staying with a multidrug suppressive regimen or switching to E/C/F/TAF plus darunavir.

Participants were adults with a viral load below 50 copies/mL for at least four months on their current regimen. All baseline regimens included ritonavir-boosted darunavir. Everyone had virologic failure with at least two antiretroviral regimens and had virus resistant to at least two antiretroviral classes. No one had a history of resistance to integrase inhibitors, but participants could be taking the integrase inhibitor raltegravir (Isentress), elvitegravir (Vitekta) or dolutegravir (Tivicay, DTG). Researchers randomized participants 2:1 to switch to E/C/F/TAF plus darunavir (800 mg) or to maintain their current regimens. The primary efficacy endpoint was percentage with a viral load below 50 copies/mL after 24 weeks by the U.S. Food and Drug Administration snapshot algorithm.


Related: Two-Drug Regimen Shines in HIV Treatment Switch Study

The 89 participants randomized to E/C/F/TAF plus darunavir and the 46 randomized to continue their baseline regimen were similar in age (median 49 and 47 years), CD4 count (median 519 and 518 cells/mm3), median number of pills in baseline regimen (five and five), proportion with two-class resistance (70% and 74%) and proportion with three-class resistance (26% and 20%). The E/C/F/TAF group included a higher proportion of men (82% versus 61%) and a lower proportion of blacks (39% versus 57%).

At week 24, E/C/F/TAF plus darunavir proved noninferior to the baseline regimen with sub-50-copy rates of 96.6% and 91.3% (difference 5.3%, 95% confidence interval [CI] -3.4% to 17.4%). At week 48, E/C/F/TAF plus darunavir met prespecified criteria for superiority to the baseline regimen with suppression rates of 94.4% versus 76.1% (difference 18.3%, 95% CI 3.5% to 33.0%). The lower 48-week virologic success rate with the baseline regimen reflected a higher rate of virologic failure with the baseline regimen (11% versus 2%) and a higher discontinuation rate (11% versus 2%).

The overall adverse event rate was higher with E/C/F/TAF plus darunavir than with the baseline regimen (92% versus 78%), but no one stopped a study drug because of an adverse event. Rates of grade 3 or 4 lab abnormalities were similar with E/C/F/TAF plus darunavir and the baseline regimen (11% and 9%). Median change in estimated glomerular filtration rate at week 48 did not differ significantly between the two regimens (+7.4 and +3.9 mL/min), but the E/C/F/TAF group had significantly greater declines in quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio).

Treatment satisfaction scores among participants were significantly higher with E/C/F/TAF plus darunavir than with the baseline regimen at weeks 24 (+28 versus +21) and 48 (+27 versus +20) (P < .001 for both). Participants assigned to E/C/F/TAF plus darunavir reported fewer days with missed doses than did those assigned to maintain the baseline regimen.

Mark Mascolini writes about HIV infection.

Related Stories

Two-Drug Regimen Shines in HIV Treatment Switch Study
Two-Drug HIV Treatment Regimens Effective in Latest Studies
Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment

This article was provided by TheBodyPRO.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.